Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus GRIS PEG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus GRIS PEG.
FULVICIN-U/F vs GRIS-PEG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Category C
Category C
Antifungal
Antifungal